Overview
NanoPhoria is a preclinical stage biotechnology company headquartered in Milan, Italy, that specializes in developing innovative inhalable cardiovascular treatments. Utilizing a proprietary non-viral nano-delivery system, NanoPhoria focuses on applications for cardiovascular diseases, such as Heart Failure with reduced Ejection Fraction (HFrEF). Their groundbreaking approach employs a nano-in-micro delivery mechanism using inorganic calcium-phosphate nanoparticles, offering flexibility for inhalation and potentially other administration routes.
Locations
- Registered Office: Via Visconti di Modrone, 18, 20122 Milan, Italy
- Operational Headquarters: Via Borgogna, 5, 20122 Milan, Italy
Contact
- Email: info@nanophoria.com
Financial Background
NanoPhoria has considerably enhanced its financial standing with a recent award of €17.5 million from the European Innovation Council's Accelerator Program. This accomplishment acknowledges the company's cutting-edge approach in cardiovascular treatment innovations. In addition, prior seed financing of €3.5 million has laid a robust foundation for the company's notable growth trajectory.
Leadership and Team
- Dr. Daniele Catalucci, PhD: Director and Founder, molecular biologist specializing in cardiovascular research.
- Claudio De Luca, PhD, MBA: CEO and Founder, experienced life science executive with 25 years in the field.
- Michele Iafisco, PhD: Co-Founder, renowned chemist focusing on nanotechnology and drug delivery systems.
- Dr. Alessio Alogna, MD, PhD: Co-Founder and cardiologist, pivotal in developing respiratory treatment strategies.
- Giovanni Ravaioli: HR Executive and Senior Strategic Advisor for team development.
- Mathieu Ghadanfar, MD, FESC, FAHA: Senior Strategic Advisor for drug development.
- Simona Marzorati, PhD: Expert Project Manager in Bioengineering.
Technological and Product Focus
NanoPhoria's flagship product, NP-MP1, is an advanced inhalable formulation that delivers a proprietary peptide designed specifically for chronic heart failure conditions. The company's technological platforms exhibit tremendous adaptability, enabling potential applications across various delivery routes, enhancing tissue-specific delivery of therapeutic compounds.
Achievements and Recognition
- EIC Funding: Securing €17.5 million from the European Innovation Council's Accelerator highlights NanoPhoria's potential and contribution within the biotechnology sector.
- Industry Acknowledgement: The company's innovations have been recognized in distinguished circles, including the American College of Cardiology, for their groundbreaking approach.
Competitive Landscape
NanoPhoria operates in a highly competitive biotech space, with several noteworthy players:
- Econic Biosciences: Focused on developing targeted therapies for cancer, specializing in extrachromosomal DNA for oncogene amplification control.
- ResoTher Pharma: Based in Holte, Denmark, it develops peptide-based drugs for cardiovascular diseases, with a keen focus on inflammation.
- Repare Therapeutics: A significant player in biotechnology, contributing to competitive advancements in this field.
These competitors, along with NanoPhoria, form a diverse and innovative arena in biotechnology, particularly in drug delivery and therapeutic solutions.
Industry Position and Prospects
NanoPhoria is well-positioned within the biotechnology sector, fortified by its pioneering developments in drug delivery systems. With its innovative platform offering extensive therapeutic applications, NanoPhoria is set to attract strategic investments and accelerate research and development. Their successful funding from the European Innovation Council not only underscores their inventive edge but strengthens their financial capacity to spearhead potential breakthroughs in the industry. Through strategic initiatives and ongoing technological advancements, NanoPhoria is poised to expand its footprint in the competitive biotech ecosystem, reinforcing its dedication to superior drug delivery solutions.
